Alnylam Pharmaceuticals (ALNY) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $165.00 -5.17%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q2 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $19.97 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $350 at Freedom Broker
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $240 at Morgan Stanley
- Lear Corp. (LEA) Tops Q3 EPS by 39c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
